LEXICON PHARMACEUTICALS INC (LXRX) — insider trading
Health Care · NASDAQ
LEXICON PHARMACEUTICALS INC (LXRX) has 25 reported SEC Form 4 insider transactions in our data (latest 2026-06-03).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | DEBBANE RAYMOND | Director | Option exercise / conversion (derivative) | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | DEBBANE RAYMOND | Director | Option exercise / conversion | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Amouyal Philippe | Director | Option exercise / conversion (derivative) | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Amouyal Philippe | Director | Option exercise / conversion | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | BARKER SAM L | Director | Option exercise / conversion (derivative) | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | BARKER SAM L | Director | Option exercise / conversion | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Cheung Ivan | Director | Option exercise / conversion (derivative) | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Cheung Ivan | Director | Option exercise / conversion | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | SOBECKI CHRISTOPHER J | Director | Option exercise / conversion (derivative) | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | SOBECKI CHRISTOPHER J | Director | Option exercise / conversion | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Sullivan Diane E. | Director | Option exercise / conversion (derivative) | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Sullivan Diane E. | Director | Option exercise / conversion | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Swain Judith L | Director | Option exercise / conversion (derivative) | 89,312 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Swain Judith L | Director | Option exercise / conversion | 89,312 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Cheung Ivan | Director | Grant / award / vesting (derivative) | 43,478 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Cheung Ivan | Director | Grant / award / vesting (derivative) | 35,714 | $0.00 | $0 | Form 4 |
| 2026-05-01 | BARKER SAM L | Director | Grant / award / vesting (derivative) | 43,478 | $0.00 | $0 | Form 4 |
| 2026-05-01 | BARKER SAM L | Director | Grant / award / vesting (derivative) | 35,714 | $0.00 | $0 | Form 4 |
| 2026-05-01 | SOBECKI CHRISTOPHER J | Director | Grant / award / vesting (derivative) | 43,478 | $0.00 | $0 | Form 4 |
| 2026-05-01 | SOBECKI CHRISTOPHER J | Director | Grant / award / vesting (derivative) | 35,714 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Amouyal Philippe | Director | Grant / award / vesting (derivative) | 43,478 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Amouyal Philippe | Director | Grant / award / vesting (derivative) | 35,714 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Artal Participations S.a r.l.; Artal International S.C.A.; Artal International Management S.A.; Artal Group S.A.; Westend S.A.; Stichting Administratiekantoor Westend; Wittouck Amaury | Director, 10% owner | Option exercise / conversion (derivative) | 408,435 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Artal Participations S.a r.l.; Artal International S.C.A.; Artal International Management S.A.; Artal Group S.A.; Westend S.A.; Stichting Administratiekantoor Westend; Wittouck Amaury | Director, 10% owner | Grant / award / vesting (derivative) | 408,435 | — | — | Form 4 |
| 2026-04-30 | Artal Participations S.a r.l.; Artal International S.C.A.; Artal International Management S.A.; Artal Group S.A.; Westend S.A.; Stichting Administratiekantoor Westend; Wittouck Amaury | Director, 10% owner | Option exercise / conversion | 20,421,735 | $0.00 | $0 | Form 4 |
Ask the chat about LXRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: LEXICON PHARMACEUTICALS INC (LXRX).
Last updated 2026-06-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.